INIS
patients
100%
hemophilia
38%
diseases
33%
levels
27%
assessments
19%
comparative evaluations
15%
cancer
15%
chemotherapy
14%
evaluation
14%
populations
12%
thrombin
11%
risks
11%
laboratories
10%
blood
10%
defects
10%
screening
10%
collagen
10%
hemostatics
9%
glycoproteins
9%
transfusions
8%
sensitivity
7%
testing
7%
aggregation
7%
adults
7%
hemorrhage
6%
peaks
6%
phenotype
6%
performance
6%
cost
6%
control
6%
genetics
6%
mutations
6%
tools
6%
netherlands
6%
therapy
6%
size
6%
genes
6%
fibrinolysis
5%
receptors
5%
management
5%
proteins
5%
design
5%
shear
5%
classification
5%
Keyphrases
Hemophilia
30%
Platelets
22%
Von Willebrand Factor
18%
Von Willebrand Disease
16%
Desmopressin (DDAVP)
15%
Thrombocytopenia
14%
Pharmacokinetics
14%
Thrombus Formation
13%
Mild Bleeding Disorders
13%
Non-severe Haemophilia
13%
Bleeding
12%
Chemotherapy
10%
Hemostasis
9%
Cancer Patients
9%
Hemophilia B
9%
Platelet Function Analyzer
9%
Integrin
9%
Multi-parameter
9%
Thrombin Generation Assay
8%
Bleeding Disorders
8%
Severe Haemophilia A
7%
Factor VIII Level
6%
Factor Concentrates
6%
Netherlands
6%
Platelet Function Disorders
6%
Platelet Transfusion
6%
Bleeding Assessment Tool
6%
Clinical Practice
6%
Factor VIII (FVIII)
6%
Hemophilia Patients
6%
Glycoprotein VI
5%
Factor VIII Concentrate
5%
Thrombin Generation
5%
Fibrinolysis
5%
Platelet Dysfunction
5%
Platelet Function
5%
Coagulation Factor Deficiency
5%
Platelet Aggregation
5%
Chemotherapy-induced Thrombocytopenia
5%
Thrombus
5%
Microfluidic Assay
5%
Medicine and Dentistry
Bleeding Disorder
23%
Haemophilia A
23%
Platelet
18%
Bleeding
16%
Desmopressin
15%
Diagnosis
14%
Thrombocyte Function
14%
Pharmacokinetics
13%
Von Willebrand Disease
13%
Thrombocytopenia
11%
Haemophilia
10%
Von Willebrand Factor
9%
Blood Stasis
9%
Haemophilia B
9%
Hemostat
9%
Integrin
9%
Glycoprotein VI
9%
Blood Clotting Factor 8
8%
Blood Clotting
8%
Disease
7%
Thrombocyte Transfusion
6%
Fibrinolysis
6%
Population
5%
Health Care Cost
5%
Cross Sectional Study
5%
Prospective Study
5%
